Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medicinal and Pharmaceutical Chemistry (3)
- Amino Acids, Peptides, and Proteins (2)
- Chemicals and Drugs (2)
- Life Sciences (2)
- Pharmaceutics and Drug Design (2)
-
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Bacterial Infections and Mycoses (1)
- Bioinformatics (1)
- Biotechnology (1)
- Cancer Biology (1)
- Cell and Developmental Biology (1)
- Computational Biology (1)
- Diseases (1)
- Genetics and Genomics (1)
- Genomics (1)
- Health Services Research (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Nanomedicine (1)
- Nanotechnology (1)
- Nucleic Acids, Nucleotides, and Nucleosides (1)
- Other Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Other Pharmacology, Toxicology and Environmental Health (1)
- Patient Safety (1)
- Pharmaceutical Preparations (1)
- Pharmacoeconomics and Pharmaceutical Economics (1)
- Pharmacology (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Keyword
-
- AMP (1)
- Antibacterial (1)
- Antimicrobial (1)
- Antimicrobial peptides (1)
- CPP (1)
-
- Cancer and bacterial Infections (1)
- Cell-penetrating peptide (1)
- Cellular Uptake (1)
- Cellular uptake (1)
- Cost-effectiveness (1)
- Cyclic-linear peptide (1)
- DC-SIGN (1)
- Diphenylalanine (1)
- Drug delivery (1)
- Gene Therapy (1)
- Gene expression (1)
- Gene therapy (1)
- Glycoprotein H (1)
- IC (1)
- ICER (1)
- KSHV (1)
- LY (1)
- Lung (1)
- Melanoma (1)
- Nanoparticles (1)
- Peptide (1)
- Peptide-drug conjugate (1)
- Phenotypic pattern (1)
- Profiling (1)
- RNA (1)
Articles 1 - 7 of 7
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Cost-Effectiveness Analysis Of Tisagenlecleucel, Blinatumomab, And Clofarabine For Treatment Of B-Cell Precursor Acute Lymphoblastic Leukemia, Kamron Lotfi
Pharmaceutical Sciences (MS) Theses
Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. …
Establishing The Role Of Dc-Sign And Glycoprotein H For Kshv Entry In B Lymphocytes, Nancy Palmerin
Establishing The Role Of Dc-Sign And Glycoprotein H For Kshv Entry In B Lymphocytes, Nancy Palmerin
Pharmaceutical Sciences (MS) Theses
Kaposi sarcoma-associated herpesvirus, also known as KSHV or HHV-8, is an emerging pathogen and the causative agent of multiple cancers in immunocompromised patients. KSHV is known to cause four types of malignancies: endothelial-based Kaposi Sarcoma (KS), two rare B cell- based lymphomas; Primary effusion lymphoma, Multicentric Castleman’s disease and a recently characterized inflammatory disorder called KSHV-associated inflammatory cytokine syndrome(KICS). Unfortunately, all of the diseases associated with KSHV infection are fatal, and to this day there is no known cure. The purpose of this study is to understand the viral entry process of KSHV in tonsil-derived B lymphocytes. This study will …
Modulation Of Antibacterial Activity And Cytotoxicity In Amphipathic Cyclic Peptide [R4w4] Using Histidine Substitution, Ryan Stueber
Modulation Of Antibacterial Activity And Cytotoxicity In Amphipathic Cyclic Peptide [R4w4] Using Histidine Substitution, Ryan Stueber
Pharmaceutical Sciences (MS) Theses
Antibiotics have been the gold standard frontline defense against bacterial infections for decades. At the same time, these infecting bacteria have continued to evolve to resist developed antibiotics in an almost endless cycle. As such, we aim to take an alternative approach utilizing antimicrobial peptides (AMPs) as a means to end this cycle. [R4W4] is among known AMPs that demonstrated antimicrobial activity against methicillin-resistant staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 2.67 μg/mL. This peptide had notably effective antimicrobial activity, especially relative to linear (R4W4). However, it displayed a concerning level of cytotoxicity; eliciting a human embryonic …
Characterization Of The Growth Factor Receptor Network Oncogenes In Lung Cancer, Ashley Duche
Characterization Of The Growth Factor Receptor Network Oncogenes In Lung Cancer, Ashley Duche
Pharmaceutical Sciences (MS) Theses
Lung cancer remains the leading cause of cancer related deaths worldwide, reportedly contributing to 1.8 million of the 10.0 million mortalities documented in the year 2020. Although advancements have been made in therapeutics and diagnostic methods, formulation of effective treatments and development of drug resistance continues to be a challenge. These challenges arise from our lack of understanding of intricate signaling pathways, such as the Growth Factor Receptor Network (GFRN), which contributes to complex lung tumor heterogeneity allowing for drug resistance development. In this study, gene expression signatures of six GFRN oncogenes overexpressed in human mammary epithelial cells (HMECs) were …
Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positive And Hydrophobic Residues As Molecular Transporters, Sorour Khayyatnejad Shoushtari
Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positive And Hydrophobic Residues As Molecular Transporters, Sorour Khayyatnejad Shoushtari
Pharmaceutical Sciences (MS) Theses
The cell membrane properties create a significant obstacle in intracellular delivery of cell-impermeable and negatively charged molecules. Amphiphilic cyclic peptides containing alternative arginine and tryptophan such as [WR]5 have been shown to enhance the transport of cargo molecules across the cell membrane. Herein, we report the synthesis and biological evaluation of a novel series of hybrid cyclic-linear peptides containing alternative positive and hydrophobic amino acids on the ring and side-chain [(RW)5]K(RW)X (X=1-5) to compare their molecular transporter efficiency. The peptides were synthesized through Fmoc solid-phase peptide synthesis. Final compounds were purified by a reversed-phase HPLC (High …
Amphiphilic Cell-Penetrating Peptides Containing Natural And Unnatural Amino Acids As Drug Delivery Tools And Antimicrobial Agents, David Salehi
Pharmaceutical Sciences (MS) Theses
Cell-penetrating peptides containing arginine as positively charged residues and tryptophan or diphenylalanine as hydrophobic residues were synthesized. The synthesis was accomplished through the Fmoc solid-phase peptide synthesis in the presence of HBTU and DIPEA. The side-chain protected linear peptides were cleaved from the resin and cyclized in the presence of DIC and HOAt in the solution phase overnight. MALDI-TOF mass spectrometry was used to characterize the peptides.
The cytotoxicity of the synthesized peptides was determined in CCRF-CEM (human, lymphoblast peripheral blood), and HEK-293 (human, embryonic epithelial kidney healthy) cells using the MTS assay. A concentration of 10 µM was found …
The Development Of A Cancer-Targeting Peptide-Drug Conjugate For The Treatment Of Melanoma, Cassandra Dill
The Development Of A Cancer-Targeting Peptide-Drug Conjugate For The Treatment Of Melanoma, Cassandra Dill
Pharmaceutical Sciences (MS) Theses
Cancer is an ongoing global pandemic which has caused a dramatic shift in research priorities. One of the most aggressive and difficult to treat has invariably remained metastatic melanoma. Although encompassing only 4% of overall skin cancer diagnoses, chances for recovery were slim until recent revolutionary development of immunotherapy adding to its regimen spectrum. This is due to its resistance to many standard-of-care treatment methods, along with its relatively high-metastatic potential. Within the past decade, eight new targeted and immune checkpoint inhibitors have gained FDA approval. The median life survival has increased significantly from 9 months to over 2 years …